 |
 |
|||||||||||||||
 |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
Phase I Combination REOLYSIN®/Radiation Therapy Trial - United Kingdom In December 2007, Oncolytics announced it had completed enrolment in its Phase Ia/Ib clinical trial to evaluate the feasability, safety and anti-tumour effects of intratumoural administration of REOLYSIN® in combination with radiation in patients with advanced cancers. Interim analysis has shown evidence of local responses and an indication of systemic effects. The primary objective of the study is to determine the maximum tolerated dose, dose limiting toxicity and safety profile of REOLYSIN®® when administered intratumourally to patients receiving radiation treatment. A secondary objective is to examine any evidence of anti-tumour activity. Patients were enrolled at the Royal Marsden and St. James's Hospitals in the U.K. See related press releases: December 21, 2007 - Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN®/Radiation Clinical Trial October 24, 2007 - Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN® and Radiation Clinical Trial September 28, 2007 - Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN® and Radiation Clinical Trial July 10, 2006 - Oncolytics Biotech Inc. Commences Patient Enrolment in Phase Ib U.K. Clinical Trial Investigating REOLYSIN® in Combination with Radiation Therapy June 20, 2006 - Oncolytics Biotech Inc. Completes Patient Enrolment in Phase Ia Combination REOLYSIN®/Radiation Clinical Trial April 4, 2006 - Oncolytics Biotech Inc. Research Collaborators to Present Reovirus Data at AACR Conference March 28, 2006 - Oncolytics Biotech Inc. to Webcast Phase I REOLYSIN®/Radiation Clinical Trial Results March 3, 2006 - Oncolytics Biotech Inc. Phase I Combination REOLYSIN®/Radiation Clinical Trial Abstract Available on AACR Website January 24, 2006 - Oncolytics Biotech Inc.’s Research Collaborators to Present Phase I Combination REOLYSIN®/Radiation Clinical Trial Data at AACR Conference July 26, 2005 - Oncolytics Biotech Inc. Commences Patient Enrolment in U.K. Clinical Trial Investigating REOLYSIN® in Combination with Radiation Therapy February 18, 2005 - Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN® in Combination with Radiation Therapy |
|
|||||||||||
 |
|
 |